Mattia Galli | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin. A pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy	EUROPEAN HEART JOURNAL. CARDIOVASCULAR PHARMACOTHERAPY	2022
Gender-differences in antithrombotic therapy across the spectrum of ischemic heart disease: Time to tackle the Yentl syndrome?	FRONTIERS IN CARDIOVASCULAR MEDICINE	2022
Pharmacodynamic profiles of dual-pathway inhibition with or without clopidogrel versus dual antiplatelet therapy in patients with atherosclerotic disease	THROMBOSIS AND HAEMOSTASIS	2022
Updated meta-analysis of randomized controlled trials on the safety and efficacy of different prophylactic anticoagulation dosing regimens in non-critically ill hospitalized patients with COVID-19	EUROPEAN HEART JOURNAL. CARDIOVASCULAR PHARMACOTHERAPY	2022
Antiplatelet therapy after percutaneous coronary intervention	EUROINTERVENTION	2022
Intracoronary bolus of glycoprotein IIb/IIIa inhibitor as bridging or adjunctive strategy to oral P2Y12 inhibitor load in the modern setting of ST-elevation myocardial infarction	MINERVA CARDIOLOGY AND ANGIOLOGY	2022
Comparative effects of guided vs. potent P2Y(12) inhibitor therapy in acute coronary syndrome. A network meta-analysis of 61 898 patients from 15 randomized trials	EUROPEAN HEART JOURNAL	2022
Efficacy and safety of dual-pathway inhibition in patients with cardiovascular disease: a meta-analysis of 49 802 patients from 7 randomized trials	EUROPEAN HEART JOURNAL. CARDIOVASCULAR PHARMACOTHERAPY	2022
Focus on the road to modelling cardiomyopathy in muscular dystrophy	CARDIOVASCULAR RESEARCH	2021
Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations	EXPERT REVIEW OF CLINICAL PHARMACOLOGY	2021
Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention. A systematic review and meta-analysis	THE LANCET	2021
Colchicine in ischemic heart disease: the good, the bad and the ugly	CLINICAL RESEARCH IN CARDIOLOGY	2021
Do We Need to Define Therapeutic Ranges for Edoxaban Plasma Concentration?	JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY	2021
Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials	EUROPEAN HEART JOURNAL. CARDIOVASCULAR PHARMACOTHERAPY	2021
Colchicine and risk of non-cardiovascular death in patients with coronary artery disease: a pooled analysis underling possible safety concerns	EUROPEAN HEART JOURNAL. CARDIOVASCULAR PHARMACOTHERAPY	2021
ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study	JOURNAL OF CARDIOVASCULAR MEDICINE	2021
Colchicine in Patients with Chronic Coronary Disease	THE NEW ENGLAND JOURNAL OF MEDICINE	2021
Intracoronary bolus of glycoprotein IIB/IIIA inhibitor as bridging or adjunctive strategy to oral P2Y(12) inhibitor load in the modern setting of STEMI	MINERVA CARDIOANGIOLOGICA	2020
Colchicine significantly increases the risk of non-cardiovascular death in patients with coronary artery disease	EUROPEAN HEART JOURNAL. CARDIOVASCULAR PHARMACOTHERAPY	2020
Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: A meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients	EUROPACE	2020